Adaptimmune Therapeutics Croissance future
Future contrôle des critères 0/6
Les bénéfices de Adaptimmune Therapeutics devraient diminuer de 6.5% par an tandis que son chiffre d'affaires annuel devrait croître de 8.6% par an. Le BPA devrait croître de en baisse de 0.5% par an.
Informations clés
-6.5%
Taux de croissance des bénéfices
-0.5%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 27.0% |
| Taux de croissance des recettes | 8.6% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Good |
| Dernière mise à jour | 24 Oct 2024 |
Mises à jour récentes de la croissance future
Recent updates
The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%
Sep 26
Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions
Sep 12Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Jul 03Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Apr 26Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Apr 16Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Feb 22Adaptimmune: Drug Approval Now Imminent?
Feb 02Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Mar 08Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Nov 09Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Sep 20We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022
Aug 10Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics
Aug 03Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
Jun 29Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
Jun 19Adaptimmune Therapeutics: A Little More Patience May Be Profitable
Mar 06Circling Back On Adaptimmune Therapeutics
Dec 15We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Dec 02Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming
Sep 29We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Aug 14Adaptimmune Therapeutics: T-Cell Therapy Pioneer Boasts A Deep Pipeline, ESMO Approaches
Jul 29Adaptimmune Therapeutics: Still The TCR Leader, And With Major Upcoming Catalysts
Jun 16Adaptimmune Therapeutics (ADAP) Investor Presentation - Slideshow
Jun 05Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 84 | -166 | -58 | -145 | 6 |
| 12/31/2025 | 45 | -189 | -60 | -205 | 9 |
| 12/31/2024 | 168 | -59 | -61 | -59 | 8 |
| 6/30/2024 | 141 | -72 | -47 | -44 | N/A |
| 3/31/2024 | 18 | -163 | -138 | -136 | N/A |
| 12/31/2023 | 60 | -114 | -146 | -141 | N/A |
| 9/30/2023 | 71 | -95 | -132 | -124 | N/A |
| 6/30/2023 | 71 | -91 | -145 | -127 | N/A |
| 3/31/2023 | 71 | -114 | -150 | -125 | N/A |
| 12/31/2022 | 27 | -165 | -172 | -142 | N/A |
| 9/30/2022 | 18 | -175 | -40 | -10 | N/A |
| 6/30/2022 | 12 | -176 | -29 | -7 | N/A |
| 3/31/2022 | 9 | -171 | -12 | 3 | N/A |
| 12/31/2021 | 6 | -158 | 2 | 11 | N/A |
| 9/30/2021 | 6 | -156 | -158 | -152 | N/A |
| 6/30/2021 | 6 | -149 | -129 | -124 | N/A |
| 3/31/2021 | 4 | -140 | -121 | -117 | N/A |
| 12/31/2020 | 4 | -130 | -56 | -54 | N/A |
| 9/30/2020 | 3 | -123 | -39 | -37 | N/A |
| 6/30/2020 | 2 | -127 | -52 | -50 | N/A |
| 3/31/2020 | 2 | -138 | -62 | -59 | N/A |
| 12/31/2019 | 1 | -137 | -116 | -113 | N/A |
| 9/30/2019 | 2 | -144 | -134 | -132 | N/A |
| 6/30/2019 | 42 | -99 | -96 | -92 | N/A |
| 3/31/2019 | 51 | -102 | -97 | -93 | N/A |
| 12/31/2018 | 60 | -96 | -109 | -104 | N/A |
| 9/30/2018 | 62 | -87 | -100 | -94 | N/A |
| 6/30/2018 | 49 | -93 | -97 | -91 | N/A |
| 3/31/2018 | 43 | -69 | N/A | -73 | N/A |
| 12/31/2017 | 38 | -70 | N/A | -54 | N/A |
| 9/30/2017 | 42 | -58 | N/A | -31 | N/A |
| 6/30/2017 | 17 | -76 | N/A | -59 | N/A |
| 3/31/2017 | 14 | -78 | N/A | -58 | N/A |
| 12/31/2016 | 14 | -72 | N/A | -48 | N/A |
| 9/30/2016 | 10 | -73 | N/A | -68 | N/A |
| 6/30/2016 | 12 | -61 | N/A | -53 | N/A |
| 3/31/2016 | 15 | -55 | N/A | -45 | N/A |
| 12/31/2015 | 14 | -48 | N/A | -32 | N/A |
| 9/30/2015 | 13 | -19 | N/A | -20 | N/A |
| 6/30/2015 | 10 | -37 | N/A | -30 | N/A |
| 3/31/2015 | 7 | -16 | N/A | -4 | N/A |
| 12/31/2014 | 4 | -12 | N/A | 24 | N/A |
| 9/30/2014 | 2 | -13 | N/A | 25 | N/A |
| 6/30/2014 | 1 | -12 | N/A | 37 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: ADAP devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: ADAP devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: ADAP devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de ADAP ( 8.6% par an) devrait croître plus lentement que le marché de US ( 8.9% par an).
Croissance élevée des revenus: Le chiffre d'affaires de ADAP ( 8.6% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ADAP devrait être élevé dans 3 ans